US 12,290,538 B2
Methods and products for treatment of gastrointestinal disorders
Mark Smith, Somerville, MA (US); Anh-Thu Elaine Vo, Somerville, MA (US); Rotem Sadovsky, Somerville, MA (US); John Henske, Somerville, MA (US); Ylaine Gerardin, Somerville, MA (US); Sonia Timberlake, Somerville, MA (US); Cosmas Giallourakis, Cambridge, MA (US); and Ewan Taylor, San Diego, CA (US)
Assigned to Finch Therapeutics Holdings LLC, Boston, MA (US); and Millennium Pharmaceuticals, Inc., Cambridge, MA (US)
Appl. No. 17/628,339
Filed by Finch Therapeutics Holdings LLC, Somerville, MA (US); and Millennium Pharmaceuticals, Inc., Cambridge, MA (US)
PCT Filed Jul. 17, 2020, PCT No. PCT/US2020/042541
§ 371(c)(1), (2) Date Jan. 19, 2022,
PCT Pub. No. WO2021/016081, PCT Pub. Date Jan. 28, 2021.
Claims priority of provisional application 63/001,888, filed on Mar. 30, 2020.
Claims priority of provisional application 62/876,350, filed on Jul. 19, 2019.
Prior Publication US 2022/0257673 A1, Aug. 18, 2022
Int. Cl. A61K 35/741 (2015.01); A61P 1/04 (2006.01)
CPC A61K 35/741 (2013.01) [A61P 1/04 (2018.01)] 15 Claims
 
1. A method of treating inflammatory bowel disease (IBD) in a subject with IBD in need thereof, the method comprising administering to the subject a plurality of bacterial isolates, wherein the plurality of bacterial isolates comprises Bacteroides stercoris and Bacteroides cellulosilyticus, and at least one of Bacteroides uniformis, Subdoligranulum variabile, Anaerostipes hadrus, Odoribacter splanchnicus, Roseburia faecis, Faecalibacterium prausnitzii, Akkermansia muciniphila, Alistipes shahii, and Eubacterium rectale, wherein the Bacteroides stercoris comprises a 16S ribosomal ribonucleic acid (rRNA) sequence that has at least 95% sequence identity with the nucleotide sequence of SEQ ID NO: 13.